Literature DB >> 21731520

American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer.

Catherine H Van Poznak1, Jamie H Von Roenn, Sarah Temin.   

Abstract

Journal of Clinical Oncology recently published ASCO's update to its guideline on the use of bone-modifying agents for patients with bone metastases, the scope of which was narrowed to the use of bone-modifying agents for patients with evidence of bone metastases.

Entities:  

Year:  2011        PMID： 21731520      PMCID： PMC3051857          DOI： 10.1200/JOP.2011.000212

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  1 in total

1.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544
  1 in total
  13 in total

Review 1.  Side effects of bone-targeted therapies in advanced breast cancer.

Authors:  Christoph Domschke; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2014-10       Impact factor: 2.860

2.  Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.

Authors:  Rodica Anghel; Alexander Bachmann; Meral Bekşac; Thomas Brodowicz; Jindřich Finek; Radko Komadina; Krzysztof Krzemieniecki; Istvan Lang; Jozef Marencak; Roger von Moos; Martin Pecherstorfer; Tamara Rordorf; Damir Vrbanec; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2013-07-06       Impact factor: 1.704

3.  N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.

Authors:  Arlindo R Ferreira; Irina Alho; Ning Shan; Margarida Matias; Mariana Faria; Sandra Casimiro; Kim Leitzel; Suhail Ali; Allan Lipton; Luís Costa
Journal:  Oncologist       Date:  2016-08-17

4.  Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.

Authors:  Ryota Tanaka; Kan Yonemori; Akihiro Hirakawa; Fumie Kinoshita; Naoki Takahashi; Jun Hashimoto; Makoto Kodaira; Harukaze Yamamoto; Mayu Yunokawa; Chikako Shimizu; Manabu Fujimoto; Yasuhiro Fujiwara; Kenji Tamura
Journal:  Oncologist       Date:  2016-03-14

5.  Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.

Authors:  Beatrice J Edwards; Sarah Usmani; Dennis W Raisch; June M McKoy; Athena T Samaras; Steven M Belknap; Steven M Trifilio; Allison Hahr; Andrew D Bunta; Ali Abu-Alfa; Craig B Langman; Steve T Rosen; Dennis P West
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

Review 6.  Cancer-associated bone disease.

Authors:  R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-10-22       Impact factor: 4.507

Review 7.  Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature.

Authors:  Ning Jia; Fionnuala C Cormack; Bin Xie; Zita Shiue; Behzad Najafian; Julie R Gralow
Journal:  BMC Cancer       Date:  2015-07-22       Impact factor: 4.430

8.  Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey.

Authors:  Brian Hutton; Patricia Morretto; Urban Emmenegger; Sasha Mazzarello; Iryna Kuchuk; Christina L Addison; Freya Crawley; Christine Canil; Shawn Malone; Scott Berry; Dean Fergusson; Mark Clemons
Journal:  J Bone Oncol       Date:  2013-06-21       Impact factor: 4.072

9.  De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.

Authors:  Brian Hutton; Christina Addison; Sasha Mazzarello; Anil A Joy; Nathaniel Bouganim; Dean Fergusson; Mark Clemons
Journal:  J Bone Oncol       Date:  2013-04-15       Impact factor: 4.072

10.  Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice.

Authors:  Nicolas Bonnet; Philippe Lesclous; Jean Louis Saffar; Serge Ferrari
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.